GlassScriptPhysician profile
Dennis G Yick
NPI 1649313370
$2,143.20
in general payments reported to CMS, 2019-2025
29 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $127 · 2023: $322 · 2024: $655 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530 · Education: $62.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.92 |
| Education | $62.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $257.25 | 2023-2025 | Tezspire |
| Insmed, INC. | $252.75 | 2024-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $205.92 | 2019-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $177.09 | 2019-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.10 | 2024-2025 | Ofev |
| Melinta Therapeutics, LLC | $124.52 | 2023 | Vabomere |
| Merck Sharp & Dohme LLC | $105.28 | 2019-2024 | Winrevair |
| Janssen Pharmaceuticals, INC | $94.51 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.61 | 2019-2020 | |
| Medtronic, INC. | $78.78 | 2024-2025 | Illumisite, Puritan Bennett |
| Baxter Healthcare | $65.39 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Metaneb System |
| Glaxosmithkline, LLC. | $53.24 | 2025 | Nucala |
| Mylan Specialty L.P. | $48.92 | 2024 | Yupelri |
| Genentech USA, INC. | $45.15 | 2019-2020 | |
| Viatris Specialty LLC | $41.78 | 2025 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $37.12 | 2019 | |
| Atos Medical INC | $35.80 | 2024 | Provox Life Home Hme |
| Astellas Pharma US INC | $33.47 | 2023 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $29.76 | 2024 | Andexxa |
| Edwards Lifesciences Corporation | $26.40 | 2024 | Hemosphere |
| La Jolla Pharmaceutical Company | $24.96 | 2019 | |
| Nabriva Therapeutics, Plc | $24.79 | 2020 | |
| Mallinckrodt Enterprises LLC | $24.19 | 2019 | |
| Verona Pharma, INC. | $21.59 | 2025 | Ohtuvayre |
| Electromed, INC. | $21.41 | 2024 | Smartvest |
| Portola Pharmaceuticals, LLC | $20.90 | 2020 | |
| Allergan, INC. | $16.21 | 2019 | |
| Philips North America LLC | $14.76 | 2023 | |
| Pfizer INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Yick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.